ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014

Size: px

Start display at page:

Download "ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014"

Osborn Tate
6 years ago
Views:

ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014 The American Medical Group Foundation (AMGF), AMGA s

1 ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014 The American Medical Group Foundation (AMGF), AMGA s Anceta Collaborative, and Humedica are pleased to announce an opportunity for AMGA member organizations who are Optum One customers to participate in an Adult Immunization Best Practices Learning Collaborative. As current Anceta participant, your organization is eligible for this exclusive program. The Best Practices Learning Collaborative is designed for organizations that are striving to improve their adult immunization rates. Working together, the participating groups will identify optimal and efficient ways to improve adult immunizations, with a specific focus on pneumococcal and influenza vaccines, leveraging the Optum One Population Analytics platform to support your initiatives. Data from Optum One shows that the median pneumococcal vaccination rates across all Anceta participants is 60% for adults > 65 years and 16% for high risk adults ages years. This is well below the Healthy People 2020 goals which are 90% for > 65 years and 60% for high-risk adults The Healthy People 2020 goal for influenza vaccination is 90% for both populations. Five (5) Anceta participants will be selected to participate. Each will receive $15,000 in educational support. The purpose of this collaborative is to increase immunization rates in adult patients, with a specific focus on pneumococcal vaccines and influenza at a minimum, thereby reducing the clinical and economic burden of vaccine preventable diseases, through a pilot campaign targeting up to five organizations on the Optum One platform. Specific objectives and benefits for all parties include: Identify gaps and ways to address gaps in recommended vaccination practices with a specific focus on pneumococcal vaccines and influenza Design and implement a variety of strategies to address gaps in practice using a combination of existing intervention tools, targeting both providers and patients, and identification of best practices. Evaluate the program s impact on relevant vaccination rates over time. Identify gaps in capture of data about vaccinations and ways to improve the accuracy and completeness of data on vaccination administration and vaccination status. Demonstrate value of a data-driven partnership in preventive care and identify opportunities for a broader national campaign. HOW DOES THE COLLABORATIVE WORK? Participating organizations will be able to regularly network with peers and have the opportunity to learn and share best practices through: Webinars (monthly or bi-monthly) Online resources such as a dedicated website for participant material-sharing and a listserv for ideasharing and collaboration Consultation with experts in the field Two in-person meetings (kick-off and wrap-up) At the end of the 12-month collaborative, AMGF will work with participating organizations to develop individual Best Practices Case Studies of their programs for publication Page 1

2 PROJECT TIMELINE October 2014 November 2014 December 2014 February 2015 Advisory Committee Nomination due, October 10, 2014 Applicants Notified, November 4, 2014 Applications due to AMGF, October 24, 2014 (5:30 pm PDT) *Endorsed by organization leadership Collaborative Orientation Webinar, November 21, 2014, 2:00pm 3:00pm ET Advisory Committee Meeting, December 9-10, 2014, AMGA Headquarters, Alexandria, VA Kick-off Meeting registration March 2015-January 2016 February 2016 March July 2016 Webinars (monthly or bimonthly) Collaborative Wrap-up Meeting. Date/Location TBD Groups to work with AMGF to develop Best Practices Case Studies Collaborative Kickoff Meeting, date/location, TBD Groups to work with AMGF & Humedica on data and rigorous qualitative research CRITERIA FOR PARTICIPATION Participating organizations must sign an agreement outlining the collaborative expectations below: 1. Create an implementation team. Integrated EHR for all physicians and sites participating within your project Patient participation as a team member is strongly encouraged Up to 4 team members are encouraged to attend the two in-person meetings (reasonable travel costs will be reimbursed) 2. Obtain high-level organizational leadership buy-in and sign-off on project. 3. Work with Humedica and Anceta to create and use reports derived from Optum One data to track performance. 4. Participate in all webinars and meetings. 5. Share tools, insights, and protocols related to the project. 6. Engage in open dialogue and discussion. 7. Review final data in May (Optum One and custom data) 8. Participate in Best Practices Case Studies. a. Agree to allow AMGF, Humedica, and Pfizer to publish information such as interventions, findings, and other supporting materials related to the project. b. AMGF to provide medical writer assistance. 9. Participate in qualitative research (interviews and/or surveys) Page 2

3 INSTRUCTIONS FOR PREPARING YOUR APPLICATION Applications are due by close of business (5:30 pm, PDT), October 24, 2014 Complete the Adult Immunization Collaborative Application Template 1. Please provide no more than a total of 5 pages. (Font Specifications: 11 Point Arial Font) Include an organizational profile that gives the reader an understanding of the size and scope of your organization (250 word limit). Provide answers for each of the 5 sections (500 word limit for each section). 2. Applications will be reviewed based on. 3. Complete the provided cover sheet template and include: Application title Organization Primary contact information (name, title, , phone, address) Sponsor signature (CEO, medical director, department head) and contact information (name, title, , phone, address) 4. Provide supporting information: You are welcome to cite and label the supporting documents in an appendix. It is highly preferred that supporting documents are clearly labeled as Appendix 1, Appendix 2, etc. If you are nominating a colleague to serve as a member of the Advisory Committee, please provide their CV in the Appendices. 5. Submit one electronic copy of the application to Joyce Jones at jjones@amga.org by close of business (5:30 pm, PDT), October 24, Questions or Comments? If you have questions or need further information, contact Danielle Casanova at dcasanova@amga.org or (703) , ext. 347 or visit our website at Page 3

4 ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014 ORGANIZATIONAL PROFILE: Include a brief organizational profile that gives the reader an understanding of the size and scope of your organization. (250 words or less) Provide a description of your Adult Immunization management program. (500 words or fewer for each section) Please address the following: 1. DESCRIBE WHAT POPULATIONS YOU CURRENTLY TARGET FOR PNEUMOCOCCAL AND INFLUENZA VACCINE PROGRAMS. (500 word limit) How any physicians (FTEs) does your organization have? How many sites do you have where pneumococcal and influenza immunization care is provided? How is your EHR used to facilitate the care process? 2. DESCRIBE YOUR CURRENT ADULT IMMUNIZATION MANAGEMENT PROGRAMS, IF ANY? (500 words) Have you defined any protocols or clinical pathways for pneumococcal and influenza vaccines? Which immunizations measures, if any, are you currently tracking? Do you have an immunization registry? 3. DESCRIBE YOUR IDEAS FOR REDESIGN FOR YOUR PNEUMOCOCCAL AND INFLUZENA VACCINATION MANAGEMENT PROGRAM? PLEASE CLARIFY IF THE PROPOSED PROGAM WILL BE A PILOT AT 1-2 SITES OR ORGANIZATION-WIDE. (500 word limit) 4. DESCRIBE THE BARRIERS OR OBSTACLES YOU EXPECT TO ENCOUNTER AND HOW YOU PLAN TO ADDRESS THEM. (500 word limit) 5. We invite you to self-nominate or nominate a colleague to participate on an Advisory committee for the Collaborative (Optional). If interested, please share a brief background on the nominee (500 word limit). In addition, please share their CV in the Appendix section. Page 4

5 APPENDICES Cite and label the supporting documents in an appendix. It is highly preferred that supporting documents are clearly labeled as Appendix 1, Appendix 2, etc. Page 5

Together 2 Goal Innovator Track: Cardiovascular Disease Cohort. Call for Participation

Together 2 Goal Innovator Track: Cardiovascular Disease Cohort Call for Participation Cardiovascular Disease (CVD) and Diabetes Approximately 28 million Americans are living with Type 2 diabetes. Due to